VB-111 is a gene-based biologic for solid tumor indications with current clinical trials in rGBM, thyroid cancer and ovarian cancer.
Thyroid cancer occurs in the thyroid gland, a hormone-producing organ at the base of the neck that regulates heart rate, blood pressure, body temperature and weight. According to the National Cancer Institute, in 2013, there were an estimated 637,115 people living with thyroid cancer in the United States, with an estimated 64,300 new cases in 2016. The type of treatment depends on the cancer cell type, tumor size and severity of the disease. First-line treatment is surgical removal of the thyroid gland, and is recommended for most patients. Treatment with radioactive iodine after surgery to destroy any remaining thyroid tissue may be recommended for more advanced disease. If radioactive iodine is ineffective, other treatments are prescribed, such tyrosine kinase inhibitors and systemic chemotherapy. However, if such treatments are unsuccessful, the therapeutic options for patients are currently very limited. In 2016, there were an estimated 1,980 deaths in the U.S. as a result of the disease. This subset of patients has an unmet need for novel therapeutic options.
We conducted an exploratory Phase 2 clinical trial in the United States to assess the safety and efficacy of single or multiple doses of VB-111.
For more information please click here.
Currently, VBL does not have an active clinical trial in Thyroid Cancer.